Dissecting the heterogeneity of the microenvironment in primary and recurrent nasopharyngeal carcinomas using single-cell RNA sequencing. (31st December 2022)

• Record Type: Journal Article
• Authors: Peng, Wen-Sa; Zhou, Xin; Yan, Wen-Bin; Li, Yu-Jiao; Du, Cheng-Run; Wang, Xiao-Shen; Shen, Chun-Ying; Wang, Qi-Feng; Ying, Hong-Mei; Lu, Xue-Guan; Xu, Ting-Ting; Hu, Chao-Su
• Is Part Of: Oncoimmunology. Volume 11:Number 1(2022)
• Publication Date: 2022-12-31
• Subjects: Nasopharyngeal carcinoma -- recurrence -- tumor microenvironment -- immune cells -- single-cell RNA sequencing; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2022.2026583
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Nasopharyngeal carcinoma (NPC) has a 10–15% recurrence rate, while no long term or durable treatment options are currently available. Single-cell profiling in recurrent NPC (rNPC) may aid in designing effective anticancer therapies, including immunotherapies. For the first time, we profiled the transcriptomes of ∼60, 000 cells from four primary NPC and two rNPC cases to provide deeper insights into the dynamic changes in rNPC within radiation fields. Heterogeneity of both immune cells (T, natural killer, B, and myeloid cells) and tumor cells was characterized. Recurrent samples showed increased infiltration of regulatory T cells in a highly immunosuppressive state and CD8 + T cells in a highly cytotoxic and dysfunctional state. Enrichment of M2-polarized macrophages and LAMP3 + dendritic cells conferred enhanced immune suppression to rNPC. Furthermore, malignant cells showed enhanced immune-related features, such as antigen presentation. Elevated regulatory T cell levels were associated with a worse prognosis, with certain receptor-ligand communication pairs identified in rNPC. Even with relatively limited samples, our study provides important clues to complement the exploitation of rNPC immune environment and will help advance targeted immunotherapy of rNPC.